ArticleScientific reports2026
Colorimetric loop-mediated isothermal amplification for the rapid and visual detection of hepatitis B virus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pilot Evaluation of Simplified HBV DNA Extraction-LAMP Workflows for Hepatitis B Molecular Testing in Resource-Limited Settings.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatitis B Virus (HBV) infection remains a major global health concern, particularly in low-resource settings where access to conventional diagnostic platforms is limited. To address this challenge, we developed and optimized a colorimetric Loop-Mediated Isothermal Amplification (LAMP) assay for the rapid and visual detection of HBV. The assay operates at a constant temperature of 65 °C for 50 min and utilizes cresol red as a pH indicator dye, producing a distinct pink-to-yellow color change in positive samples. Analytical validation demonstrated a limit of detection (LoD) of 10 ng/µL, and no cross-reactivity was observed with Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) confirming assay specificity. Clinical evaluation of 200 qPCR-confirmed HBV-positive plasma samples and 20 qPCR-confirmed negative donor plasmas, the colorimetric LAMP assay achieved a sensitivity of 62.0% (124/200; 95% CI 54.9–68.8) and a specificity of 100.0% (20/20; 95% CI 83.2–100.0). Notably, sensitivity exceeded 90% for samples with viral loads ≥ 10,000 IU/mL (log₁₀ ≥4.0) when evaluated against the Cobas HBV real-time PCR assay. This LAMP-based platform offers a rapid, cost-effective, and user-friendly diagnostic tool, particularly suitable for point-of-care use in resource-limited settings. Its deployment could significantly enhance early HBV detection, inform timely clinical management, and contribute to broader efforts in HBV control and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.